|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Pulmonology Institute (Drs. Fink, Krelbaum, Bendayan, and Kramer), Rabin Medical Center, Beilinson Campus, Petah Tiqva; the Department of Thoracic Surgery (Dr. Yellin), Sheba Medical Center, Tel Hashomer; Carmel Medical Center (Dr. Saute), Haifa; and the Pulmonary Institute, Hadassah University Hospital (Dr. Glazer), Jerusalem, Israel.
Correspondence to: Mordechai R. Kramer, MD, FCCP, Pulmonology Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel; e-mail: pulm{at}netvision.net.il
| Abstract |
|---|
|
|
|---|
Methods: Retrospective analysis of the clinicopathologic data and outcome of patients from four major hospitals in Israel in the last 20 years.
Results: There were 142 cases of pulmonary carcinoid tumors: typical (n = 128) and atypical (n = 14). We calculated an annual incidence of about 2.3 to 2.8 cases per 1 million population. The ratio of female to male patients was 1.6:1. The prevalence of smoking was similar to the general population in patients with typical carcinoids and twice as high in the atypical group. Bronchial obstruction was the cause of most of the presenting symptoms and signs and included obstructive pneumonitis, pleuritic pain, atelectasis, and dyspnea (41%). Carcinoid syndrome was extremely rare and occurred in only one patient with metastatic disease. Most of the tumors (68%) arose in the major bronchi. Diagnosis was made using fiberoptic bronchoscopy in 52% of patients without evidence of endobronchial hemorrhage. Nodal involvement and distant metastases occurred in 57% and 21%, respectively, in the atypical group, and 10% and 3%, respectively, in the typical group. The treatment of choice was surgical: lobectomy (56%) or pneumonectomy (16%). The respective 5-year survival rates for patients with typical and atypical tumors were 89% and 75% (not significant), and the 10-year survival rates were 82% and 56% (p < 0.05). A review of large series from the literature is presented.
Conclusion: Pulmonary carcinoid is an uncommon tumor in the Israeli population. With early diagnosis and aggressive surgical therapy, long-term prognosis is excellent.
Key Words: pulmonary carcinoid pulmonary obstruction
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
Smoking
Forty-two of the 128 patients with typical carcinoid tumor (33%)
smoked > 10 pack-years at the time of diagnosis, as compared to 9 of
the 14 patients with atypical tumors (64%; p < 0.05).
Presenting Symptoms
The majority of patients in our series presented with evidence of
bronchial obstruction (n = 58; 41%): obstructive pneumonitis,
pleuritic pain, atelectasis, and dyspnea (Table 1
). This was followed by cough in 50 patients (35%), hemoptysis in 33
patients (23%), and a variety of other symptoms/signs, including
weakness, nausea, weight loss, night sweats, neuralgia,
hyperparathyroidism, and Cushings syndrome that occurred in 22
(15%). Forty-three patients (30%) were asymptomatic at presentation.
Carcinoid syndrome was extremely rare and occurred in only one patient
with metastatic disease.
|
Tumor Size
The lesions ranged in size (maximum dimension) from 0.3 to 7.5 cm,
with 47% of the neoplasm having a maximum dimension of
3.0 cm.
Mean lesion size was 2.8 + 1.9 cm.
Tumor Location
Most of the carcinoid tumors (68%) arose in the major bronchi:
approximately 13% in the mainstem bronchi and 55% in the lobar
bronchi (Table 2 ). A third of the tumors (32%) originated in the periphery of the
lungs, ie, at the segmental bronchi or beyond. In our study,
the neoplasm was located in the right lung in 60% of patients and in
the left lung in 40%. The most common site was the right middle lobe
(23%).
|
|
Treatment
Surgery was performed in 138 patients: lobectomy in 77 patients
(56%), wedge resection in 18 patients (13%), bilobectomy in 9
patients (7%), pneumonectomy in 22 patients (16%), segmentectomy in 4
patients (3%), and sleeve resection in 4 patients (3%). One patient
underwent endobronchial laser therapy. One patient refused surgery, and
in three patients the tumor was considered inoperable.
Survival
We were able to assess 5-year survival in 102 patients (90 with
typical carcinoid and 12 with atypical carcinoid) and 10-year survival
in 73 patients (64 with typical carcinoid and 9 with atypical
carcinoid; Fig 1
). The overall 5-year and 10-year survival rates were 87% and 79%,
respectively. The 5-year survival rate was 89% in the typical
carcinoid group and 75% in the atypical carcinoid group (not
significant), and 10-year survival was 82% and 56%, respectively
(p < 0.05).
|
| Discussion |
|---|
|
|
|---|
The prevalence of smokers among the typical carcinoid group is close to that in the adult population of Israel for the last 20 years.13 However, the figure is twice as high in the atypical carcinoid group, indicating a possible association between atypical carcinoids and smoking. This is supported by earlier studies as well.14 15
Despite previous reports, endobronchial biopsies were quite safe in our hands without significant bleeding. In the peripheral lesions, the yield of fine-needle aspiration was 69% in our hands, which is slightly higher than that reported by Bertelsen and colleagues,16 but not reaching the impressive yield of 96% achieved by Anderson et al.17
The occurrence of a third of our tumors in the periphery explains the high (43%) rate of asymptomatic patients at presentation. In the study of Okike et al,18 only 16% of 203 patients had peripheral carcinoid tumors, whereas Marty-Ane et al19 found more peripheral than central carcinoids in their small study of 23 patients. Right middle lobe involvement was high in our series, as was reported by Ranchod and Levine,20 but in contrast with Okike et al,18 in which the most common sites of tumors were the right and left lower lobes.
As in our series, previous reports3 12 13 14 15 16 pointed out that regional nodal involvement in typical carcinoid tumors is low and ranges from 3 to 20%, unlike the atypical carcinoids, in which nodal metastasis ranges from 48 to 75%. Distant metastases are quite rare in the typical group, but quite common in the atypical group.
Long-term results vary in the literature: Todd and colleagues,21 in a study conducted in 65 patients with carcinoid tumors, reported a survival rate of only 65% at 5 years, whereas Stamatis et al,22 in 210 patients with typical carcinoids, reported 5-year and 10-year survival rates of 98% and 95%, respectively. The 10-year survival in our atypical group is similar to that reported by Okike et al,18 which reached 57%. Table 4 summarizes 640 cases in the literature in the last 20 years (1984 to 2000) with sufficient data. Mean age is 52 years, and the male to female ratio is 1.1 in favor of the female patients. Location in most series is central (64%), and typical carcinoid is reported in 81% of cases. Lobectomy was sufficient in 42 to 69% of cases, and pneumonectomy was performed in 6 to 16% of cases. As seen, prognosis is excellent in most series, and survival is approximately 88% at 5 years and 81% at 10 years.
|
| Conclusion |
|---|
|
|
|---|
| Acknowledgements |
|---|
Received for publication May 31, 2000. Accepted for publication January 23, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. L. Young, J. D. Mitchell, C. Cool, and S. P. Nana-Sinkam Wheezing and Exertional Dyspnea in a 25-Year-Old Mountaineer Chest, March 1, 2008; 133(3): 820 - 825. [Full Text] [PDF] |
||||
![]() |
F. Rea, G. Rizzardi, A. Zuin, G. Marulli, S. Nicotra, R. Bulf, M. Schiavon, and F. Sartori Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 186 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lemaitre, Z. Mansour, E. A. Kochetkova, C. Koriche, X. Ducrocq, J.-M. Wihlm, E. Quoix, and G. Massard Bronchoplastic lobectomy: do early results depend on the underlying pathology? A comparison between typical carcinoids and primary lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 168 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut, June 1, 2005; 54(suppl_4): iv1 - iv16. [Full Text] [PDF] |
||||
![]() |
W. Hamilton and D. Sharp Diagnosis of lung cancer in primary care: a structured review Fam. Pract., December 1, 2004; 21(6): 605 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cardillo, F. Sera, M. Di Martino, P. Graziano, R. Giunti, L. Carbone, F. Facciolo, and M. Martelli Bronchial carcinoid tumors: nodal status and long-term survival after resection Ann. Thorac. Surg., May 1, 2004; 77(5): 1781 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mezzetti, F. Raveglia, T. Panigalli, L. Giuliani, F. Lo Giudice, S. Meda, and S. Conforti Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification Ann. Thorac. Surg., December 1, 2003; 76(6): 1838 - 1842. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hage, A. B. de la Riviere, C.A. Seldenrijk, and J.M. M. van den Bosch Update in Pulmonary Carcinoid Tumors: A Review Article Ann. Surg. Oncol., July 1, 2003; 10(6): 697 - 704. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |